Hangzhou Jiuyuan Genetic Biopharmaceutical Co (HKSE:02566) EBIT: HK$183 Mil (TTM As of Dec. 2025)


HKSE:02566 Hangzhou Jiuyuan Genetic Biopharmaceutical Co Ltd HKSE:02566
20 GF Score
Price HK$5.79
! 1 Warning Sign
View Full Analysis

What is Hangzhou Jiuyuan Genetic Biopharmaceutical Co EBIT?

Hangzhou Jiuyuan Genetic Biopharmaceutical Co HKSE:02566 -2.03% 20 EBIT is HK$183 Mil as of Dec. 2025. GuruFocus rates HKSE:02566 with a GF Score™ of 20/100. The stock has 1 warning sign investors should review.

Hangzhou Jiuyuan Genetic Biopharmaceutical Co's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was HK$67 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$183 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Hangzhou Jiuyuan Genetic Biopharmaceutical Co's annualized ROC % for the quarter that ended in Dec. 2025 was 8.45%. Hangzhou Jiuyuan Genetic Biopharmaceutical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 13.15%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Hangzhou Jiuyuan Genetic Biopharmaceutical Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 24.14%.

Hangzhou Jiuyuan Genetic Biopharmaceutical Co  (HKSE:02566) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Hangzhou Jiuyuan Genetic Biopharmaceutical Co's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=131.43 * ( 1 - 15.77% )/( (1355.301 + 1266.378)/ 2 )
=110.703489/1310.8395
=8.45 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2230.533 - 233.759 - ( 641.473 - max(0, 352.792 - 1587.302+641.473))
=1355.301

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2339.777 - 284.112 - ( 789.287 - max(0, 367.201 - 1638.485+789.287))
=1266.378

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Hangzhou Jiuyuan Genetic Biopharmaceutical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=133.082/( ( (428.692 + max(625.8, 0)) + (470.959 + max(498.133, 0)) )/ 2 )
=133.082/( ( 1054.492 + 969.092 )/ 2 )
=133.082/1011.792
=13.15 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(709.456 + 165.185 + 0.021999999999935) - (233.759 + 0 + 15.104)
=625.8

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(630.862 + 165.429 + 14.974) - (284.112 + 0 + 29.02)
=498.133

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Hangzhou Jiuyuan Genetic Biopharmaceutical Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=183.446/759.998
=24.14 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hangzhou Jiuyuan Genetic Biopharmaceutical Co EBIT Related Terms

Hangzhou Jiuyuan Genetic Biopharmaceutical Co EBIT Historical Data

* Premium members only.

The historical data trend for Hangzhou Jiuyuan Genetic Biopharmaceutical Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hangzhou Jiuyuan Genetic Biopharmaceutical Co EBIT Chart

Hangzhou Jiuyuan Genetic Biopharmaceutical Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
168.06 67.52 157.85 187.67 184.69

Hangzhou Jiuyuan Genetic Biopharmaceutical Co Semi-Annual Data
Dec21 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial 35.18 143.85 45.00 116.91 66.54

HKSE:02566 vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Hangzhou Jiuyuan Genetic Biopharmaceutical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hangzhou Jiuyuan Genetic Biopharmaceutical Co EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hangzhou Jiuyuan Genetic Biopharmaceutical Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Hangzhou Jiuyuan Genetic Biopharmaceutical Co's EV-to-EBIT falls into.


HKSE:02566
20GF Score
Hangzhou Jiuyuan Genetic Biopharmaceutical Co Ltd HKSE:02566
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hangzhou Jiuyuan Genetic Biopharmaceutical Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$183 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of HK$183 Mil mean?
Hangzhou Jiuyuan Genetic Biopharmaceutical Co (HKSE:02566) has a EBIT of HK$183 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Hangzhou Jiuyuan Genetic Biopharmaceutical Co.
Is Hangzhou Jiuyuan Genetic Biopharmaceutical Co's EBIT too high?
Hangzhou Jiuyuan Genetic Biopharmaceutical Co's current EBIT is HK$183 Mil. Overall, Hangzhou Jiuyuan Genetic Biopharmaceutical Co has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Hangzhou Jiuyuan Genetic Biopharmaceutical Co's EBIT compare to VRTX and REGN?
Hangzhou Jiuyuan Genetic Biopharmaceutical Co's EBIT of HK$183 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Hangzhou Jiuyuan Genetic Biopharmaceutical Co. Hangzhou Jiuyuan Genetic Biopharmaceutical Co's current EBIT is HK$183 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hangzhou Jiuyuan Genetic Biopharmaceutical Co stock overvalued right now?
Hangzhou Jiuyuan Genetic Biopharmaceutical Co (HKSE:02566) has a current EBIT of HK$183 Mil. The current EBIT is HK$183 Mil. Hangzhou Jiuyuan Genetic Biopharmaceutical Co's overall GF Score™ is 20/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Hangzhou Jiuyuan Genetic Biopharmaceutical Co (HKSE:02566), the current EBIT is HK$183 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hangzhou Jiuyuan Genetic Biopharmaceutical Co Business Description

Address No. 23, Eighth Street, Baiyang Street, Qiantang District, Zhejiang Province, Hangzhou, CHN
Hangzhou Jiuyuan Genetic Biopharmaceutical Co Ltd is a biopharmaceutical company in China. It is engaged in the research & development, manufacturing, and commercialization of biopharmaceutical products and medical devices. The company focuses on four large and fast-growing therapeutic areas: orthopedics, metabolic diseases, oncology, and hematology. Centered around these therapeutic areas, it has built a diversified product portfolio comprising several marketed products, such as Jilifen, Jijufen, Jiouting, Yinuojia, Guyoudao, etc., and has several product candidates under development, such as JY54, JY23, JY47, JY56, JY29-2, etc., targeting various indications. Geographically, the company generates maximum revenue from the Chinese Mainland, and the rest from other countries.
20GF Score

Get the complete analysis for HKSE:02566

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$5.79
Price